About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 108 record(s)
Req # A-2020-001873
Adverse Drug Reactions (ADRs). Report numbers: E2B_03503796, E2B_03507790, E2B_03511982, E2B_03514556, 000926168, E2B_03638780, E2B_02235102, E2B_03587031, E2B_03606462, E2B_03561359, E2B_03620807, E2B_03586427, E2B_03600568, E2B_03628906, E2B_02559463, E2B_03563778, E2B_03628905, E2B_02606561, E2B_03532135, E2B_03627942.Organization: Health Canada
October 2021
Req # A-2020-001909
Adverse Drug Reactions (ADRs). Report numbers: E2B_03062327, 000736878, E2B03230373.Organization: Health Canada
October 2021
Req # A-2021-000001
Adverse Drug Reaction (ADR): Report number: E2B_03585278.Organization: Health Canada
October 2021
Req # A-2021-000086
Adverse Drug Reactions (ADRs). Report numbers: 000928261, E2B_03443761, E2B_03597413.Organization: Health Canada
October 2021
Req # A-2021-000263
Adverse Drug Reactions (ADRs) for Amisulpride. Report numbers: E2B_03468307, E2B_03443807, E2B_03468397, E2B_03452094, E2B_03452133.Organization: Health Canada
October 2021
Req # A-2021-000282
Adverse Drug Reaction (ADR) for PLAQUENIL. Report number: E2B_03706156.Organization: Health Canada
October 2021
Req # A-2021-000322
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-104711-198.Organization: Health Canada
October 2021
Req # A-2021-000325
Adverse Drug Reactions (ADRs). Report numbers: E2B_02222416, E2B_02099156, 000722876, E2B_02133821, E2B_02163148, E2B_02188878, E2B_02188883, E2B_02201797, E2B_01560931, E2B_03222896, E2B_02604134, E2B_02704921, E2B_02865433, E2B_02504356, E2B_02503075.Organization: Health Canada
October 2021
Req # A-2021-000353
Adverse Drug Reaction (ADR) for ROSUVASTATIN CALCIUM. Report number: E2B_03467451.Organization: Health Canada
October 2021
Req # A-2021-000372
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03820452.Organization: Health Canada
October 2021